The German Breast Group conducts research into breast cancer, developing and implementing its own study concepts.
With the help of additional scientific research projects, we strive to gain further insights into this disease.
We are delighted to inform you that the results of the GeparOcto phase III study designed to compare a sequential dose-dense, dose-intensified (idd) ETC (epirubicin, paclitaxel, cyclophosphamide) with weekly PM(Cb) (paclitaxel, liposomal doxorubicin, carboplatin) for neoadjuvant treatment of patients with high-risk early breast cancer have been published in the European Journal of Cancer.
Prof. Dr. Sibylle Loibl gehört im Jahr 2018 mit Ihrer Arbeit im Bereich der Brustkrebsforschung zu den 1% der am meisten zitierten Wissenschaftlern.
We are delighted to inform you that the results of an interim analysis from KATHERINE, a phase III open-labeled trial, have been published in the New England Journal of Medicine.
Further results from the prospective PANTHER trial focused on obese breast cancer patients treated with adjuvant tailored dose-dense chemotherapy versus standard treatment have been published in the Annals of Oncology.
Data of several GBG trials and translational research projects will be presented at the upcoming SABCS 2018 Congress, which will take place from 4-8 December in San Antonio, Texas, USA.
Every month, we present an interesting paper.
We are proud to inform you that our article A multicentre, randomised, double-blind, phase II study to evaluate the tolerability of an induction dose escalation of everolimus in patients with metastatic breast cancer (DESIREE; GBG 86) is now available online.